Sea Chung, MD
Internal Medicine · Flushing, NYNPI 1073671400
Payments from drug & device makers
Across 724 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$1K
- Amarin Pharma, Inc.$1K
- Lilly USA, LLC$971
- Ardelyx, Inc.$940
- Merck$786
- plus $8K from 32 others
What the payments were for
- Food & beverage$14,797100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $1,521 |
| Gilead | 55 | $1,453 |
| Amarin Pharma, Inc. | 61 | $1,145 |
| Lilly USA, LLC | 49 | $971 |
| Ardelyx, Inc. | 42 | $940 |
| Merck | 38 | $786 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $778 |
| Pfizer | 42 | $759 |
| Nestle Healthcare Nutrition Inc. | 26 | $731 |
| Novo Nordisk | 37 | $696 |
| Amgen | 34 | $654 |
| Sanofi-aventis U.S. LLC | 28 | $638 |
| AstraZeneca | 25 | $456 |
| Sumitomo Pharma America, Inc. | 24 | $446 |
| Axsome Therapeutics, Inc. | 15 | $437 |
| Ironwood Pharmaceuticals, Inc | 22 | $420 |
| Boehringer Ingelheim | 15 | $293 |
| Lundbeck LLC | 11 | $204 |
| Otsuka America Pharmaceutical, Inc. | 9 | $180 |
| Johnson & Johnson | 8 | $149 |
| Corium, LLC | 9 | $148 |
| Novartis | 2 | $145 |
| GSK | 7 | $136 |
| Bayer | 7 | $128 |
| Vivus LLC | 4 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Sunovion Pharmaceuticals Inc. | 5 | $76 |
| Sanofi Pasteur Inc. | 3 | $61 |
| Exact Sciences | 3 | $52 |
| Intercept Pharmaceuticals, Inc. | 2 | $52 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Vifor Pharma, Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Insmed, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENPEP$607
- Vemlidy$125
- ENTRESTO$120
- SOLIQUA 100/33$103
How this compares
$14,827 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 1,959 | $789,793 |
| Diclofenac Epolamine | 1,221 | $698,517 |
| ProliaDenosumab | 240 | $410,604 |
| TrintellixVortioxetine Hydrobromide | 675 | $386,698 |
| LinzessLinaclotide | 616 | $384,148 |
| JardianceEmpagliflozin | 416 | $319,051 |
| CreonLipase/Protease/Amylase | 239 | $215,010 |
| JanuviaSitagliptin Phosphate | 196 | $147,655 |
| MyrbetriqMirabegron | 291 | $145,528 |
| RybelsusSemaglutide | 131 | $142,318 |
| ZenpepLipase/Protease/Amylase | 119 | $130,151 |
| GemtesaVibegron | 239 | $126,653 |
| TradjentaLinagliptin | 139 | $103,971 |
| EliquisApixaban | 130 | $92,915 |
| RestasisCyclosporine | 121 | $78,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Restasis | $1,521 | $678,060976 claims |
| Boehringer IngelheimJardiance, Tradjenta | $293 | $423,022555 claims |
| AmgenProlia | $654 | $410,604240 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $778 | $396,259701 claims |
| MerckJanuvia, Janumet, Janumet Xr | $786 | $231,183309 claims |
| Novo NordiskRybelsus, Ozempic | $696 | $206,493187 claims |
| Aimmune Therapeutics, Inc.Zenpep | $25 | $130,151119 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $446 | $126,653239 claims |
| PfizerEliquis | $759 | $92,915130 claims |
| GSKBreo Ellipta | $136 | $59,974141 claims |
| Johnson & JohnsonXarelto, Invokana | $149 | $54,29389 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $456 | $52,583105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.